June 21, 2017 / 1:17 PM / 2 months ago

BRIEF-GSK says Shingrix phase 3 study met main goal

June 21 (Reuters) - Glaxosmithkline Plc:

* Presents positive results from phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's advisory meeting

* Study met its primary objective of demonstrating non-inferior immune response

* Shingrix was well-tolerated in both study groups when assessed up to one month after second dose of Shingrix Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below